Rigor Reviewed

Rigor-Reviewed Manuscript

A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial

Name: Αlpha¹ Rigor Record — A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial
Item: A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial
Rating: 59
Author: Αlpha¹

Xu Z, Ren F, Wang P, Cao J, Tan C, Ma D, Zhao L, Dai J, Ding Y, Fang H, Li H, Liu H, Luo F, Meng Y, Pan P, Xiang P, Xiao Z, Rao S, Satler C, Liu S, Lv Y, Zhao H, Chen S, Cui H, Korzinkin M, Gennert D, Zhavoronkov A.

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 1★ (Critical), 0 critical, 0 high issues for “A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 10, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

1 / 5

Critical — serious problems across many checks

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×6−3★
ClaimsOverstated claim ×3−1.5★
ReportingStatistical analysis not met−0.5★
ReportingKey resources partially met−0.25★

Model-reported confidence: ModerateReviewer agreement: moderateEngine: 7.29.0Source: full text

Not verified in this report

References were not verified against Crossref/OpenAlex.
No reported statistical tests were found to recompute.

Problems surfaced8 types

Numerical inconsistencies2

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed
Mathematically impossible statisticAssessed

Overstated conclusions2

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Conclusions overstated beyond the evidenceAssessed
Conclusions only partially backed by the presented evidenceAssessed

Data authenticity concerns1

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Other integrity concernAssessed

Reporting gaps2

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Statistical reporting inadequateAssessed
Key resources under-identified (antibodies, cell lines, RRIDs)Assessed

Copyediting1

Wording, consistency and formatting errors that need correcting before submission.

Wording or formatting errors that need correctingAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

Automated narrative synthesis was unavailable for this run; this verdict is the majority vote of the independent reviewers, with their own suggestions listed as action items.

Fallback synthesis: the narrative synthesizer did not return a usable result, so the report is assembled directly from the reviewers.

12 major claims checked against the paper's own evidence: 3 not fully backed by the presented evidence (unsupported or overstated).

Efficacy claim is anchored to an adequate endpoint and a meaningful effect.

6 integrity concerns flagged (0 high).

Reporting

Eight Dimensions6 pass · 1 warn · 1 fail

The introduction cites prior studies on TNIK as a target for IPF, AI-driven drug discovery, and limitations of current therapies. It acknowledges that no AI-discovered drug has progressed through phase 3, providing a clear rationale for the trial. The hypothesis that TNIK inhibition may treat IPF follows from the cited evidence.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 85% conf

The paper clearly establishes the scientific premise: AI-driven drug discovery has few clinical successes, IPF lacks disease-modifying therapies, and the authors previously identified TNIK via AI and advanced rentosertib through phase 0/1 trials.

Evidence

direct quote[Main, paragraph 2]

“Despite these advancements, few AI-discovered or AI-designed drugs have reached clinical trials.”